Psilocybin and Bipolar Disorder: Careful Clinical Studies are Warranted, Survey Study Suggests
Results from recently published survey studies on the effect of psilocybin and bipolar disorder offered support for the design of future clinical trials.
In a recent study published in the Journal of Psychopharmacology, researchers conducted a web-based international survey with 541 participants who self-reported a diagnosis of bipolar disorder (BP) and had used psilocybin to achieve a “full psychedelic trip” (1). In addition to multiple choice questions, the survey also offered the option for respondents to answer an open-ended question and leave comments about their experiences with psilocybin.
“Before we run clinical trials to investigate the effectiveness of psilocybin for people with bipolar disorder, we need to know whether it’s safe for them to use, as some medications which have a similar neurobiological mechanism of action can trigger manic episodes,” said study author Emma Morton, a Canadian Institutes of Health Research Banting Postdoctoral Fellow at the University of British Columbia (2). “That’s why we turned to community members to ask about their experiences.”
Responses to survey questions indicated mixed experiences to psilocybin (2). On average, participants rated the harmfulness of their experience as 1.6 out of 5, and the helpfulness as a 4. However, a third of respondents reported new or increasing manic symptoms, difficulty sleeping, and anxiety. Use of emergency medical services occurred for 18 participants and was considered rare in this study.
“Respondents (even those who experienced adverse effects) indicated that psilocybin use was more helpful than harmful,” read part of the results (2). “Quantitative findings elaborated on perceived benefits, as well as the potential for psilocybin trips to contain both positively and negatively received elements.”
Following the Phase I study, interviews with 15 of the respondents were conducted to further understand their psilocybin use to determine the cause of negative outcomes. “We learned that contextual factors like dose, setting, use of other substances, or pre-existing sleep problems, may have had a role in whether people experienced positive or negative outcomes,” Morton explained. “This finding emphasizes how important it will be to conduct additional research under controlled conditions to be more confident about the potential risks and benefits of psilocybin use for bipolar disorder.”
“Our findings demonstrate both benefits and risks of psilocybin use in this population,” read part of the conclusion (3). “Carefully designed clinical trials focused on safety and preliminary efficacy are warranted.”
References
Ep 27: Tracking Strains in Diverse Landscapes
July 2nd 2025In this latest installment of Noid Knowledge, we are joined by Daniela Vergara, PhD, Hemp Specialist at the Cornell Cooperative Extension, and Anna Schwabe, PhD, Associate Lecture Professor at the University of Colorado, discussing the evolution of cannabis cultivation and the need for regional climate data. Their recent project, funded by the Agricultural Genomics Foundation, studies 10 cannabis varieties grown by farmers in different regions, specifically plant characteristics, soil type, and harvest metrics. They aim to understand how environmental factors affect cannabis yield and quality, providing actionable insights for farmers and breeders.
Ep 26: Innovations in Drying and Curing to Protect Flower Quality
May 27th 2025In this latest installment of Noid Knowledge, we are joined by Dr. Allison Justice, Founder and CEO of the Hemp Mine, and David Sandelman COO, CTO & Co-Founder of Cannatrol. Here, Allison and David discuss innovations in cannabis drying and curing, focusing on the Cannatrol technology which controls vapor pressure, preserving trichome integrity, and flower quality. Additionally, Allison shares how the Cannabis Research Center and Coalition (CRC) is transition to an open-source model to support cultivators, researchers, and home growers.
